On Oct. 24, 2007 Shares of Protalix BioTherapeutics Inc fell as much as 84 percent to a lifetime low, a day after the biopharmaceutical company offered to sell 10 million shares at a huge discount. Protalix, which is developing a drug to treat a rare genetic disorder known as Gaucher disease, offered the shares at $5 each, representing a discount of 86 percent to the stock's Oct. 23, 2007 closing price of $36.36. David Burke, a spokesman for the company, confirmed the pricing, but declined to talk about why the shares had been sold at such a discount. In July, Protalix said the company or some shareholders may periodically sell up to $200 million of its shares.

If you are a current shareholder or purchased shares during the period of January 1, 2007 through October 24, 2007 and would like to discuss your options of exercising your rights as a shareholder, please contact us.
Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.